Refuge Biotechnologies, a company researching ways to use CRISPR gene editing to make cancer treatment more precise, has raised $25 million in financing to continue work on its preclinical drug pipeline.
China-based 3SBio and Sequoia China led the Series B round of investment in the Menlo Park, CA, company.
CRISPR-Cas9 technology uses modified versions of the Cas9 enzyme to bind to DNA and cut it, turning off the gene. Refuge says it has developed a way to modify the enzyme so it no longer cuts DNA. This “dead Cas9” still targets areas of the genome but it only activates when it… Read more »
UNDERWRITERS AND PARTNERS